stockrow
Saturday 7 November 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million.
- EPS
- +96.5%
- Free cash flow
- +23.1%
Quarter to June 2026, against a year earlier
1.24
0.03
−2.36%
Follow APVO
Alert me
Aptevo Therapeutics Inc. (APVO) P/E ratio
Aptevo Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 217× (December 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.9× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 6.4× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 217×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)